| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Alpelisib (JAN/USAN/INN); Piqray (TN) | ||||||
| Product | VIJOICE (Novartis Pharmaceuticals Corporation), PIQRAY (Novartis Pharmaceuticals Corporation) | ||||||
| Formula | C19H22F3N5O2S | ||||||
| Exact mass | 441.1446 | ||||||
| Mol weight | 441.4705 | ||||||
| Structure |  | ||||||
| Class | Antineoplastic DG03139 PI3K inhibitor | ||||||
| Remark |
| ||||||
| Efficacy | Antineoplastic, Phosphatidylinositol 3-kinase inhibitor | ||||||
| Disease | Breast cancer (HR-positive, HER2-negative, PIK3CA-mutated) [DS:H00031] | ||||||
| Target | PIK3CA* [HSA_VAR:5290v1] [HSA:5290] [KO:K00922] | ||||||
| Network |
| ||||||
| Pathway |
| ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors L01EM03 Alpelisib D11011 Alpelisib (JAN/USAN/INN) <US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Alpelisib D11011 Alpelisib (JAN/USAN/INN) Drug groups [BR:br08330] Antineoplastic DG03139 PI3K inhibitor D11011 Alpelisib Target-based classification of drugs [BR:br08310] Enzymes Transferases (EC2) Phosphotransferase PIK3CA* [HSA_VAR:5290v1] D11011 Alpelisib (JAN/USAN/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11011 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11011 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11011 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D11011 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 30 1 C8y C 15.0500 -22.8900 2 N5x N 15.4000 -24.2900 3 C8y C 16.8000 -24.2900 4 C8y C 17.2900 -22.9600 5 S2x S 16.1700 -22.1200 6 N1b N 13.8600 -22.1900 7 C5a C 12.6700 -22.8900 8 N1y N 11.4800 -22.1900 9 O5a O 12.6700 -24.2900 10 C1y C 11.4800 -20.7900 11 C1x C 10.1500 -20.3700 12 C1x C 9.3100 -21.4900 13 C1x C 10.1500 -22.6100 14 C5a C 12.6700 -20.0900 15 N1a N 13.8600 -20.7900 16 O5a O 12.6700 -18.6900 17 C8y C 18.4800 -22.2600 18 C1a C 17.6008 -25.4384 19 C8x C 19.6981 -22.9501 20 C8x C 20.9048 -22.2403 21 N5x N 20.9634 -20.8403 22 C8y C 19.6753 -20.1502 23 C8x C 18.4686 -20.8600 24 C1d C 19.6476 -18.7602 25 C1a C 18.4386 -18.0938 26 C1d C 20.8622 -18.0261 27 X F 22.0747 -17.3261 28 C1a C 18.4659 -19.4743 29 X F 21.5622 -19.2385 30 X F 20.1622 -16.8137 BOND 32 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 1 5 1 6 6 1 1 7 6 7 1 8 7 8 1 9 7 9 2 10 8 10 1 11 10 11 1 12 11 12 1 13 12 13 1 14 8 13 1 15 14 15 1 16 10 14 1 #Up 17 14 16 2 18 17 4 1 19 3 18 1 20 17 19 1 21 19 20 2 22 20 21 1 23 21 22 2 24 22 23 1 25 17 23 2 26 22 24 1 27 24 25 1 28 24 26 1 29 26 27 1 30 24 28 1 31 26 29 1 32 26 30 1 |